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ORIGINAL ARTICLE
Chronic obstructive pulmonary disease (COPD) 
is currently the sixth leading cause of death
worldwide.1 It is noteworthy that its prevalence
and mortality are the highest in the Western
Pacific region.2 fFollowing the Global Initiative o
Obstructive Lung Disease (GOLD) guidelines,3 the
Taiwanese Society of Pulmonary and Critical Care
Medicine has issued guidelines for the diagnosis
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Background/Purpose: To compare the efficacy and safety of tiotropium and ipratropium in patients with
chronic obstructive pulmonary disease (COPD) in Taiwan.
Methods: xThis double-blind, randomized, placebo-controlled, parallel group study was conducted at si
hospitals in Taiwan. COPD patients aged ≥ 40 years, with a forced expiratory volume in 1 second (FEV1)
≤ 65% of predicted and FEV1/forced vital capacity (FVC) ≤ 70% were enrolled. After a 2-week screening/
baseline period, 132 patients were randomized to receive 4 weeks of treatment with either tiotropium
18 μg once daily from a dry powder inhaler (HandiHaler®) or two puffs of ipratropium 20 μg four times
daily from a metered dose inhaler. The primary outcome was the change in trough FEV1 from baseline to
week 4. The secondary outcome measures were trough FVC response, FEV1 and FVC responses at 2 hours
postinhalation.
Results: After 4 weeks, trough FEV1 had increased by 61.7 ± 25.3 mL for tiotropium but decreased by 16.4 ±
27.9 mL for ipratropium. The difference between groups was significant (p < 0.05; 95% CI, 10–146.1). The
trough FVC also increased by 137.2 ± 49.3 mL for tiotropium but was decreased by 84.5 ± 54.5 mL for ipra-
tropium (p < 0.001; 95% CI, 89.0–354.3). No major drug-related adverse events associated with tiotropium
and ipratropium were observed.
Conclusion: Tiotropium 18 μg once daily using HandiHaler® was significantly more effective than ipra-
tropium 40 μg four times daily in improving trough FEV1 and FVC over a 4-week period. The safety pro-
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and management of COPD.4 Airflow limitation
with a persistently low forced expiratory volume
in 1 second (FEV1) and forced vital capacity (FVC)
is characteristic of COPD.5 Parasympathetic vagal
tone is considered to be an important reversible
component of COPD, and anticholinergics are rec-
ommended as one of the first-line agents by GOLD.
Ipratropium bromide is an anticholinergic
medication used effectively and safely in the treat-
ment of COPD. However, its duration of action 
is limited to about 4–6 hours post-dose, and the
agent is a nonselective blocker of muscarinic re-
ceptor subtypes. Blockade of M2 receptor subtype
explains the paradoxical bronchoconstriction that
is observed with ipratropium in some patients.6
Tiotropium bromide is a selective antagonist
at the M1 and M3 subtypes of muscarinic recep-
tors and dissociates slowly from the receptors.
The long duration of action and receptor selec-
tivity confers certain advantages for tiotropium
over ipratropium. Clinical studies have demon-
strated better lung function in patients treated
with tiotropium compared to ipratropium.7–10
This is the first multicenter study comparing
the efficacy and safety of tiotropium and ipra-
tropium in the management of COPD in Taiwan.
It was designed to evaluate and compare the 
efficacy and safety of tiotropium from a dry pow-
der inhaler (HandiHaler®, Boehringer Ingelheim
GmbH, Ingelheim, Germany) once daily and
ipratropium from a metered dose inhaler (MDI)
four times daily in patients with stable COPD. 
Methods
Patients
Patients were required to have a diagnosis of
COPD with FEV1 ≤ 65% of predicted value and
FEV1/FVC ≤ 70%. The predicted normal values
were based on the COPD guidelines issued by
the Taiwanese Society of Pulmonary and Critical
Care Medicine.4 Patients were aged ≥ 40 years
with a smoking history of more than 10 pack-
years. Patients were excluded if they had a his-
tory of asthma, myocardial infarction, cardiac
arrhythmias, allergic rhinitis, active tuberculosis
or presence of any significant laboratory abnor-
malities or other serious medical problems. In ad-
dition, patients were excluded if they required
yregular use of daytime oxygen. Patients with an
known hypersensitivity to anticholinergic agents,
lactose or any component of inhalation capsule
were excluded. Patients with prostate hypertrophy,
bladder neck obstruction, cystic fibrosis, bronchi-
rectasis, life-threatening pulmonary obstruction o
narrow angle glaucoma were also excluded.
Study design
This was a double-blind, randomized, placebo-
xcontrolled, parallel group study conducted at si
yhospitals in Taiwan. The study was approved b
the joint institutional review board and the insti-
tutional review boards of participating hospitals.
Written informed consent was obtained from all
patients before any study procedure was under-
taken. This study was conducted in accordance
fwith good clinical practice and the Declaration o
Helsinki. Patients were screened and baseline pa-
rameters were determined during a 2-week period,
after which they were treated with study medica-
tion for 4 weeks. Trough FEV1 and FVC measure-
ments were performed on days 15 and 29.
Oral corticosteroids, inhaled corticosteroids,
theophylline and mucolytic agents without bron-
tchodilators were permitted only if stabilized for a
least 6 weeks prior to study commencement, and
ythe dose was to remain stable throughout the stud
fperiod. Oral corticosteroids were allowed only i
not exceeding a dose equivalent to < 10 mg pred-
nisolone once daily or < 20 mg prednisolone on
alternate days. Antihistamines, cromolyn sodium,
nedocromil sodium, inhaled long-acting beta-
adrenergics, beta-blockers, oral beta-adrenergics
and other investigational drugs were not allowed
for at least 1 month before the screening period.
To control exacerbations during the treatment pe-
riod, fenoterol and antibiotics were allowed as nec-
essary. Two periods of a 7-day temporary increase 
in the dose of oral steroids/theophylline or addi-
tion of oral steroids were allowed during exacer-
bations. If these medications were used during the
fTiotropium in the treatment o  COPD in Taiwan
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scheduled visits to perform pulmonary function,
the testing was postponed by at least 2 days but
not by more than 7 days after the last increased or
added medication. Ipratropium oral inhalation
was allowed during the 2-week baseline period.
During the 2-week baseline period, patients pre-
viously on ipratropium/fenoterol combination
(Berodual®, Boehringer Ingelheim GmbH) or
ipratropium/salbutamol (Combivent®, Boehringer
Ingelheim GmbH) were switched to separate ipra-
tropium and fenoterol or salbutamol MDI at a daily
dose identical to their prescribed dose of Berodual®
or Combivent®, which was discontinued at the
randomization visit. Patients entered information
about additional therapy and investigational drug
intake in a diary card, in order to assess compliance.
At the randomization visit, patients received
either tiotropium 18 μg once daily (Spiriva®,
Boehringer Ingelheim GmbH) plus ipratropium
matched placebo four times daily or tiotropium
matched placebo once daily plus ipratropium 40μg
(Atrovent®, Boehringer Ingelheim GmbH) four
times daily. Each dose of tiotropium or tiotropium
matched placebo was inhaled from a dry powder
inhaler (HandiHaler®) daily between 8.00 and
11.00 hours. Ipratropium (two puffs of 20 μg) or
ipratropium matched placebo was inhaled from
a MDI between 8.00 and 11.00 hours, at lunch,
dinner and at bedtime.
Measurements
Before entry and at the completion of the study,
patients underwent a medical examination, 12-
lead electrocardiogram and laboratory testing. At
each scheduled visit that took place on the day of
randomization, days 15 and 29, patients under-
went pulmonary function testing (FEV1 and FVC)
immediately before dosing in the seated posi-
tion, which was defined as the trough FEV1, and
again at 2 hours postdose, which was defined as
the peak FEV1. The tests were performed in tripli-
cate, and the highest FEV1 and FVC were recorded
after examining all the acceptable curves, even
if they did not come from the same curve. For 
the consistency of the data, the same spirometer
model (SU 6000 SuperSpiro Spirometer, Micro
Medical Ltd, Chatham, Kent, UK) was used by all
participating hospitals. At each scheduled visit,
details of adverse events, patients’ diary card en-
tries and concomitant medications were recorded,
and patients were requested to complete the pa-
tient evaluation questionnaire (based on cough
frequency, cough severity, chest discomfort, dys-
pnea, ease in bringing up sputum, need for PRN
bronchodilators, and global evaluation).
Statistical analysis
tThis was a superiority study. An intention-to-trea
approach was used for efficacy analysis. Each pa-
tient was randomly assigned to one of the two
ttreatment groups in a 1:1 manner. If a patien
fdiscontinued the study early due to worsening o
COPD, the missing efficacy data were estimated
by the least favorable data. If a patient missed a
visit due to other reasons, the missing data were
estimated by the last observed data. For paramet-
ric methods, the unpaired t test was used for con-
tinuous variables and analysis of covariance was
used for any significant covariates. For nonpara-
metric methods, the Wilcoxon rank sum test was
used for continuous variables and the Wilcoxon
tsigned rank test was used to test change or percen
change from baseline in each group. A descriptive
summary of demographic data was listed and
ganalyzed. Efficacy outcome was analyzed usin
parametric methods. The change from baseline
in blood pressure and pulse was analyzed ac-
cording to parametric methods. Adverse events
were coded by using the thesaurus of adverse
reaction terms (COSTART) system.11
Results
Of 175 patients screened for entry into the study,
43 were not eligible, 67 were randomly assigned
to the tiotropium group and 65 to the ipra-
tropium group. The groups were well balanced
for all demographic and baseline data (Table 1).
The withdrawals (seven patients in each group)
were similar in both treatment groups (Table 2).
In both groups, more than 89% of subjects
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completed the treatment and more than 80%
consumed adequate study medication.
Trough FEV1 and FVC
The mean baseline trough FEV1 at the start of the
tstudy did not differ between the two treatmen
groups. At the end of the study, a mean increase
of 61.7 ± 25.3 mL in the trough FEV1 was seen in
fthe tiotropium group but a mean decrease o
16.4 ± 27.9 mL was seen in the ipratropium group.
tThe difference between groups was significan
(p < 0.05; 95% CI, 10–146.1) (Figure).
Similarly, the change from baseline in trough
FVC showed a statistically significant difference
between groups. At the end of the study, the mean
trough FVC was increased by 137.2 ± 49.3 mL in
the tiotropium group and was decreased by 84.5 ±
54.5 mL in the ipratropium group (p = 0.001; 95%
CI, 89.0–354.3) (Figure).
FEV1 and FVC at 2 hours postdose (peak)
The FEV1 and FVC responses at 2 hours postdose
(peak) did not differ between groups (for FEV1
p = 0.887, for FVC p = 0.083). The increase in FEV1
and FVC values at 2 hours postdose compared to
the baseline was significant in both groups (p <
0.05) (Figure). Between-group differences in FEV1
and FVC at 2 hours postdose were numerically in
favor of tiotropium, but did not reach statistical
significance.
Table 1. Demographic and pulmonary function
data of randomized patients
Tiotropium Ipratropium
(n = 67) (n = 65)
Sex (M/F) 66/1 63/2
Age range (yr) 54.6–87.3 57.4–89.6
Height* (cm) 165.7 ± 6.2 165.5 ± 5.6
Weight* (kg) 62.3 ± 11.8 63.8 ± 9.6
Theophylline use 47 (70.1%) 47 (72.3%)
Smoking (pack-years) 36.2 38.9
FEV1 at trough* (mL) 1077 ± 392 1114 ± 333
FEV1 at 2 hr 1170 ± 418 1242 ± 330
postdose* (mL)
FVC at trough* (mL) 2007 ± 581 2109 ± 547
FVC at 2 hr 2216 ± 605 2297 ± 473
postdose* (mL)
*Data expressed as mean ± standard deviation.
Table 2. Randomized and withdrawn patients
Randomized
Tiotropium Ipratropium
(n = 67) (n = 65)
Completed study drug, 60 (89.6) 58 (89.2)
n (%)
Early termination, n (%) 7 (10.4) 7 (10.8)
Lack of efficacy 1 1
Withdrew due to 1 1
adverse event
Withdrew consent 1 2 (3.1)
Lost to follow-up 3 (4.5) 1









































iF gure. h l f f b l k h d kMean c anges in ung unction rom ase ine to 4 wee s in troug  an  pea  FEV1 dan  FVC. Tiotropium group n = 63, ipratropium
group n = 58. *p < 0.05.
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Use of rescue medications
During the treatment period (a total of 4 weeks),
this study provided rescue medicine to be used
when required. The number of rescue medica-
tion indicated the occasions of using fenoterol
(Berotec® MDI 200 μg/puff, Boehringer Ingelheim
GmbH). In both groups, about 60% of patients
used a rescue medication at least once during the
treatment period. The median occurrences of res-
cue medications used were four occasions (range,
0–166) in the tiotropium group and 10 (range,
0–234) in the ipratropium group. The mean values
were 24.7 and 25 for the tiotropium and ipra-
tropium groups, respectively. No significant dif-
ference between groups was observed in the use
of rescue medications.
Change in score for patient evaluation
questionnaire
The score decreased in both groups, by a mean of
1.98 ± 0.42 in tiotropium recipients and by 2.05 ±
0.46 in ipratropium recipients. No significant 
difference between groups was observed in the
change from baseline in the patient evaluation
questionnaire.
Safety
A list of common adverse events is given in Table
3. The overall incidences of adverse events re-
rported during the treatment period were simila
between the two treatment groups (p = 0.822).
All events were reported regardless of causal
f relationship to study medications. A total o
34 episodes of adverse events were reported dur-
ing the course of the study (from screening to the
end of the study), with 15 reported by patients 
in the tiotropium group and 19 by ipratropium
Tpatients. Adverse events were coded by COSTAR
fand categorized by body system. The intensity o
ymost reported events was mild or moderate; onl
one episode reported in the tiotropium group
was graded “severe”. The causal relationship was
assessed by the investigator in a blinded manner.
Only one event in the tiotropium group and two
in the ipratropium group were assessed as “yes”.
The only adverse event classified as being related
to tiotropium was the urinary frequency changing,
which was mild in intensity. The drug-related ad-
verse events in the ipratropium group were atrial
fibrillation in one patient, and lung disorder in
another patient. (The coded term “lung disorder”
referred to the signs of symptoms of COPD with
acute exacerbation.) These two reports were mod-
erate in intensity. The baseline laboratory data
ywere comparable between the groups. The onl
comparison between groups that showed signifi-
cant change over time was a higher atypical lym-
phocyte count in tiotropium recipients compared
to ipratropium recipients (p = t0.03). This was no
deemed to be clinically relevant. No other signi-
ficant change in vital signs and physical exami-
nations were observed in either treatment group
throughout the study.
Discussion
In this study, the bronchodilator effect of tiotro-
 pium was compared with that of ipratropium
 in COPD patients. After 4 weeks of treatment,
18 μg of tiotropium once daily via HandiHaler®
achieved a significantly greater improvement in
Table 3. Incidence of adverse events and relationship to study
medications
Adverse events Tiotropium Ipratropium
p
(COSTART) (n = 67) (n = 65)
Patients with any adverse event 13 11 0.822
Total adverse events 15 14
Relatively common adverse event*





Causal relationship of adverse event
Yes‡ 1 2
No 14 17
*Only incidence of at least 3% in any treatment group is presented; †the coded term
“Lung disorder” referred to the signs of symptoms of COPD with acute exacerbation
and “Gout” referred to gouty arthritis; ‡the only drug-related adverse event in the
tiotropium group is lung disorder, and the two drug-related adverse events in the ipra-
tropium group are atrial fibrillation and lung disorder. 
trough FEV1 and FVC than 40 μg ipratropium
with a MDI four times daily. These data con-
firm the 24-hour bronchodilating effect of
tiotropium and is in agreement with results of
previous studies.7–9 The improvement in FEV1
with tiotropium seen 24 hours after the previous
dose was superior to the FEV1 found 6 hours
after inhalation of ipratropium. The improve-
ment in FEV1 and FVC at 2 hours postdose was
significant in both groups, without any differ-
ences between groups.
The rate of FEV1 decline is considered to be
the gold standard parameter of disease progres-
sion, and has been used in a number of land-
mark studies to assess the long-term impact of
airway medications.7,9 To date, no inhaled treat-
ment has been shown to reduce the loss of lung
function in patients with COPD. The residual 
effects 24 hours after inhalation reflect the
long duration of action of tiotropium. A post 
hoc analysis of two 1-year studies suggested an
impact of tiotropium on lung function decline
when the slope was calculated from day 8 of
treatment until 1 year.12 The UPLIFT trial13 pro-
spectively examines whether tiotropium reduces
the rate of lung function decline over time. It
also assesses quality of life, exacerbations, hospi-
talizations and mortalities. The first results from
this study are expected in 2008.
In our study, the use of concomitant rescue
medication was similar in both groups, and pa-
tient evaluation questionnaires also showed no
differences between groups. Both groups showed
a statistically significant decrease in COPD symp-
toms according to the patient questionnaire. In
another study7 comparing tiotropium with ipra-
tropium, the reduction in use of concomitant
salbutamol was greater in the tiotropium group
than in the ipratropium group. In our study, the
reduction in the use of concomitant medication
was similar in both groups; this could be because
of the shorter treatment duration (4 weeks) com-
pared to that of Vincken et al7 (13 weeks). During
long-term maintenance therapy, the acute and
chronic effect of tiotropium can achieve better
bronchodilatation.
tSince cholinergic response is one of the mos
yimportant reversible components of COPD, earl
commencement of anticholinergic treatment and
the selection of anticholinergic agent play a vital
ypart in patient management. Data from our stud
agree with those from published studies7–10,14
that have shown that tiotropium has greater ben-
efits than ipratropium in multiple outcomes
including FEV1, FVC, transitional dyspnea index,
occurrence of exacerbations and health-related
yquality of life. The use of tiotropium once dail
can be considered as a first-line bronchodilator in
the management of stable stage II moderate to
stage IV very severe COPD.
yIn our study, urinary frequency was the onl
treatment-related adverse event in the tiotrop-
ium group (1.5%). Atrial fibrillation (1.5%) and
lung disorders (1.5%) were the treatment-related
adverse events observed with ipratropium. In
long-term studies of tiotropium, the most fre-
yquently reported adverse reaction was dr
mouth, generally mild in intensity and often re-
solving with continued treatment.7–9 Common
adverse reactions were constipation, moniliasis,
sinusitis and pharyngitis, occurring with frequen-
cies within 1% and 2% of placebo. In the clinical
trials of tiotropium vs. ipratropium published to
date,7–9 the safety profiles of tiotropium and
ripratropium have been similar. Although olde
anticholinergic compounds (e.g. atropine) have
been thought to impair mucociliary clearance,12
no adverse effect of the newer quaternary ammo-
nium compounds,15,16 including ipratropium,17
on this important host defense mechanism has
been demonstrated.
In summary, in agreement with most compar-
ative studies of a long-acting bronchodilator with
ipratropium,18–20 rtiotropium has shown greate
benefits than ipratropium in patients with COPD
with respect to efficacy outcomes. Importantly,
tiotropium may have potential to reverse the
decline in FEV1 in contrast to ipratropium. Con-
sequently, tiotropium might be considered to be
one of the first-line single anticholinergic agents
for the treatment of stable stage II moderate to
stage IV very severe COPD.
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